ArticleCancer cell2012
A big step for SIRT7, one giant leap for Sirtuins… in cancer.
Article in Cancer cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- HIV-1 Vpr activates host CRL4-DCAF1 E3 ligase to degrade histone deacetylase SIRT7.Virology journal · 2021Article
- K-Ras-ERK1/2 accelerates lung cancer cell development via mediating H3Pharmaceutical biology · 2019Article
- A Click Chemistry Approach Reveals the Chromatin-Dependent Histone H3K36 Deacylase Nature of SIRT7.Journal of the American Chemical Society · 2019Article
- Sirtuin-7 knockdown inhibits the growth of endometrial cancer cells by inducing apoptosis via the NF-κB signaling pathway.Oncology letters · 2019Article
- Sirtuin 7 plays an oncogenic role in human osteosarcoma via downregulating CDC4 expression.American journal of cancer research · 2017Article
- Novel protein-protein interactions of TPPII, p53, and SIRT7.Molecular and cellular biochemistry · 2015Article
- Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes.Clinical & translational immunology · 2015Article
- SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients.PloS one · 2015Article
Corrections and comments
- Comment on
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently reporting in Nature, Barber et al. demonstrated that SIRT7 maintains critical features that define cancer cells by removing the acetylation mark on lysine 18 of histone H3. Interestingly, hypoacetylation of H3K18 has been described as a general marker of tumor prognosis and oncoviral transformation.
Identifiers
22698398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.